Read more about the article First study in the world to evaluate efficacy and safety of the antismoking drug varenicline for smokers with Diabetes

First study in the world to evaluate efficacy and safety of the antismoking drug varenicline for smokers with Diabetes

Post author:Chiara Nobis
Post published:21 June 2022
Post category:Diasmoke Press Release

A recent randomized controlled trial of varenicline (Chantix) combined with psychological support has significantly increased the chance of quitting smoking for 300 smokers with type 2 diabetes mellitus

The first review to assess the metabolic impact of stopping smoking in patients with diabetes mellitus revealed serious gaps in the literature

Post author:Chiara Nobis
Post published:20 June 2022
Post category:Diasmoke Press Release

Quitting smoking can reduce cardiovascular and kidney failure risks. However, it can lead to side effects such as weight gain. A scoping review conducted by a pool of European researchers revealed a lack of data on the metabolic effects of smoking and smoking cessation in diabetes. Healthcare professionals should not assume that cessation of smoking will improve metabolic parameters in patients with diabetes.

Monday 22 March – kick off meeting of the research project Diasmoke 2.0

Post author:valeria
Post published:15 March 2021
Post category:

On Monday 22 March from 9.30 to 17.00 CET, on the Zoom platform, the CoEHAR (Center of Excellence for the acceleration of Harm Reduction) will hold the kick off meeting…